Stock Scorecard



Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $165.51 as of 9/16/2025 11:55:49 AM EST

Total Score

8 out of 30

Safety Score

53 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LGND

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LGND

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LGND

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LGND

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LGND (53 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LGND

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation 9/16/2025 12:00:00 PM
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - Elutia ( NASDAQ:ELUT ) 9/16/2025 12:00:00 PM
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update 8/18/2025 12:00:00 PM
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates 8/12/2025 12:14:00 PM
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND ) 8/12/2025 3:46:00 AM
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering 8/12/2025 3:46:00 AM
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 8/11/2025 11:00:00 AM
Ligand ( LGND ) Q2 Revenue Jumps 15% 8/7/2025 1:10:00 PM
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance 8/7/2025 11:00:00 AM
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Medtronic ( NYSE:MDT ) 7/31/2025 8:01:00 PM

Financial Details for LGND

Company Overview

Ticker LGND
Company Name Ligand Pharmaceuticals Inc - Class B
Country USA
Description Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/5/2025

Stock Price History

Last Day Price 165.51
Price 4 Years Ago 154.46
Last Day Price Updated 9/16/2025 11:55:49 AM EST
Last Day Volume 315,460
Average Daily Volume 272,636
52-Week High 169.49
52-Week Low 93.58
Last Price to 52 Week Low 76.86%

Valuation Measures

Trailing PE N/A
Industry PE 21.60
Sector PE 41.00
5-Year Average PE 21.79
Free Cash Flow Ratio 13.17
Industry Free Cash Flow Ratio 13.48
Sector Free Cash Flow Ratio 29.67
Current Ratio Most Recent Quarter 5.45
Total Cash Per Share 12.57
Book Value Per Share Most Recent Quarter 42.68
Price to Book Ratio 3.90
Industry Price to Book Ratio 29.02
Sector Price to Book Ratio 32.08
Price to Sales Ratio Twelve Trailing Months 17.23
Industry Price to Sales Ratio Twelve Trailing Months 44.43
Sector Price to Sales Ratio Twelve Trailing Months 19.62
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 19,494,500
Market Capitalization 3,226,534,695
Institutional Ownership 100.29%

Dividends

Ex-Dividend Date 7/2/2010
Previous Dividend Amount 0.0000
Current Dividend Amount 0.4560
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage -96.96%
3-Year Dividend Growth Rate Percentage -96.96%
5-Year Dividend Growth Rate Percentage -96.96%
All-Time Dividend Growth Rate Percentage -96.96%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 103.20%
Annual Earnings Growth -107.73%
Reported EPS 12 Trailing Months -4.04
Reported EPS Past Year 2.93
Reported EPS Prior Year 5.71
Net Income Twelve Trailing Months -75,864,000
Net Income Past Year -4,032,000
Net Income Prior Year 52,154,000
Quarterly Revenue Growth YOY 14.70%
5-Year Revenue Growth 6.80%
Operating Margin Twelve Trailing Months 20.40%

Balance Sheet

Total Cash Most Recent Quarter 245,020,000
Total Cash Past Year 72,307,000
Total Cash Prior Year 22,954,000
Net Cash Position Most Recent Quarter 168,230,000
Net Cash Position Past Year -4,388,000
Long Term Debt Past Year 76,695,000
Long Term Debt Prior Year 76,695,000
Total Debt Most Recent Quarter 76,790,000
Equity to Debt Ratio Past Year 0.92
Equity to Debt Ratio Most Recent Quarter 0.92
Total Stockholder Equity Past Year 830,439,000
Total Stockholder Equity Prior Year 700,913,000
Total Stockholder Equity Most Recent Quarter 828,529,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 39,974,000
Free Cash Flow Per Share Twelve Trailing Months 2.05
Free Cash Flow Past Year 95,226,000
Free Cash Flow Prior Year 46,056,000

Options

Put/Call Ratio 0.50
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 6.34
MACD Signal 7.06
20-Day Bollinger Lower Band 83.72
20-Day Bollinger Middle Band 131.17
20-Day Bollinger Upper Band 178.62
Beta 0.84
RSI 67.53
50-Day SMA 118.38
150-Day SMA 89.23
200-Day SMA 93.46

System

Modified 9/16/2025 3:50:24 AM EST